Table 1.
A summary of the existing published data for the commercially available tests in this comparison.
| Tests | Manufacturer | Target Antigen | Type | Sens† | Spec | # Samples/Patients* | Days post symptom onset |
|---|---|---|---|---|---|---|---|
| Abbott-N18 | Abbott-N | Nucleoprotein | CLMIA | 100.0% (day 17) | 99.9% | 689/125 | ≥ 21 |
| Roche-N19 | Roche Cobas | Nucleoprotein | ECLIA | 99.5% | 99.8% | 496/102 | ≥ 14 |
| Roche-S20 | Roche Cobas | Spike protein | ECLIA | 96.6% | 100% | 1485‡/331 | ≥ 15 |
| MSD13 | Meso Scale Discovery | Nucleoprotein | ECLIA | 87.2% | 92.8% | 196/196 | ≥ 21 |
| Spike protein | 97.9% | 97.4% | 47/47 | ≥ 21 | |||
| RBD (receptor binding domain) | 93.6% | 92.3% | 47/47 | ≥ 21 |
The corresponding antigen target and published sensitivity, specificity, positive predictive value and negative predictive value (if available).
ECLIA Electro Chemiluminescent Immunoassay, CLMIA chemiluminescent microparticle immuno assay, PPV positive predictive value, NPV negative predictive value, Sens sensitivity, Spec specificity, ELISA enzyme linked immunosorbent assay.
†The highest reported sensitivity.
‡233 of these samples were tested at ≥ 15 days post PCR diagnosis.
*For sensitivity testing.